Lassen Therapeutics

Lassen Therapeutics Develops Antibodies as Potential Treatments for Fibrosis, Rare Diseases, and OncologyThe company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting the IL-11 receptor α (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a key mediator of fibrosis, and blocking its activity may prove more effective than targeting other factors such as TGF-β and CTGF. IL-11 also acts as a critical effector in the organization of the tumor microenvironment and tumor growth, playing a significant mediating role between cancer and stromal cells.